1.51 BONUS! Study Time Reduction Using Surrogate End Points with Dr. Emerson Chen

Plenary Session

English - April 02, 2019 19:27 - 25 minutes - 27.3 MB - ★★★★★ - 732 ratings
Science Health & Fitness Medicine medicine oncology health policy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 1.50 Replacing RCTs, Physicians on Twitter, Open-Access, & Orthopedics with Dr. Kathryn Schabel

Next Episode: 1.52 BILCAP & DOACs for Thromboprophylaxis in Patients with Cancer with Dr. Sven Olson

In this BONUS episode, we sit down for a quick interview with Dr. Emerson Chen of OHSU on his recent paper in JAMA Internal Medicine on how using surrogate end points as opposed to overall survival for FDA approval for oncology drugs only results in a reduced drug development time of approximately 11 months.

Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351

Back us on Patreon! www.patreon.com/plenarysession